<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603341</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 19115</org_study_id>
    <nct_id>NCT02603341</nct_id>
  </id_info>
  <brief_title>Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial</brief_title>
  <official_title>Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pragmatic randomized clinical trial of patients with locally advanced breast cancer&#xD;
      randomized to either proton or photon therapy and followed longitudinally for cardiovascular&#xD;
      morbidity and mortality, health-related quality of life, and cancer control outcomes. Quality&#xD;
      of life is the outcome measure for the estimated primary completion date of August, 2022,&#xD;
      www.radcomp.org.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because no one knows which radiation treatment is best, if you decide to take part in this&#xD;
      study, you will be randomly assigned to 1 of 2 treatment groups, and then you will begin&#xD;
      radiation treatment according to usual medical practice. Randomly assigning you to a group&#xD;
      helps makes sure that each group has a similar mix of patients and makes the study better -&#xD;
      and is only done when doctors are not sure whether one treatment is better than the other.&#xD;
      You have an equal chance of getting into either treatment group, like a coin flip. Both you&#xD;
      and your doctor will be told which treatment you will get.&#xD;
&#xD;
      No matter which group patients are in, doctors will work very carefully to reduce the&#xD;
      radiation to healthy tissues. Both groups will followed for at least 10 years after&#xD;
      completing radiation therapy. The results of this study will help decide which radiation is&#xD;
      best for future patients with your type of breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2032</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of proton therapy vs. photon therapy</measure>
    <time_frame>10 years</time_frame>
    <description>Compare the effectiveness of proton vs. photon therapy in reducing major cardiovascular events (MCE), defined as atherosclerotic coronary heart disease or other heart disease death, myocardial infarction, coronary revascularization, or hospitalization for major cardiovascular event (heart failure, valvular disease, arrhythmia, or unstable angina).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the non-inferiority of proton vs. photon therapy in reducing ipsilateral breast cancer local-regional recurrence and in reducing any recurrence, defined as the first reported breast cancer recurrence of any type (local-regional or distant or cancer-specific mortality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 years</time_frame>
    <description>Compare the effectiveness of proton vs. photon therapy in improving patient-reported body image and function, fatigue and other measures of health-related quality of life (HRQOL) (anxiety, social roles, financial toxicity, general satisfaction) and adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Dose and Quality of Life and Cardiac Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Develop predictive models to examine the association of radiation dose distribution (to heart and other normal tissues) and major cardiovascular events and quality of life outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long Term Survival</measure>
    <time_frame>15 years</time_frame>
    <description>To assess longer-term rates of breast cancer specific and overall survival and development of second malignancies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1278</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Photon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Photon therapy: once a day, 5 days a week, for 5 to 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proton therapy: once a day, 5 days a week, for 5 to 7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon</intervention_name>
    <description>Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks</description>
    <arm_group_label>Photon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton</intervention_name>
    <description>Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks</description>
    <arm_group_label>Proton</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females or males diagnosed with pathologically (histologically) proven invasive&#xD;
             mammary carcinoma (ductal, lobular or other) of the breast who have undergone either&#xD;
             mastectomy or lumpectomy with any type of axillary surgery or axillary sampling.&#xD;
&#xD;
          -  For patients who have undergone lumpectomy, any type of mastectomy and any type of&#xD;
             reconstruction (including no reconstruction) are allowed.&#xD;
&#xD;
          -  For patients who have undergone lumpectomy, there are no breast size limitations.&#xD;
&#xD;
          -  Patients with non-metastatic breast cancer are eligible. This includes American Joint&#xD;
             Committee on Cancer (AJCC) 7th edition left- or right-sided breast cancer clinical or&#xD;
             pathologic stage I, II, III or loco-regionally recurrent at time of diagnosis. For&#xD;
             patients that receive neoadjuvant chemotherapy, AJCC 7th edition left- or right-sided&#xD;
             breast cancer pathologic stage yp 0, I, II, III are eligible.&#xD;
&#xD;
          -  Bilateral breast cancer is permitted. Patients with bilateral breast cancer will be&#xD;
             stratified as left-sided.&#xD;
&#xD;
          -  Must be proceeding with breast/chest wall and nodal radiation therapy including&#xD;
             internal mammary node treatment.&#xD;
&#xD;
          -  Must have a pertinent history/physical examination within 90 days prior to&#xD;
             registration.&#xD;
&#xD;
          -  Age ≥ 21 years&#xD;
&#xD;
          -  ECOG Performance Status 0 - 2 (asymptomatic to symptomatic but capable of self-care)&#xD;
             within 90 days prior to randomization.&#xD;
&#xD;
          -  Confirmation that the patient's health insurance will pay for the treatment in this&#xD;
             study (patients may still be responsible for some costs, such as co-pays and&#xD;
             deductibles). If the patient's insurance will not cover a specific treatment in this&#xD;
             study and the patient still wants to participate, confirmation that the patient would&#xD;
             be responsible for paying for any treatment received.&#xD;
&#xD;
          -  Patients who are HIV positive are eligible, provided they are under treatment with&#xD;
             highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200&#xD;
             cells/microliter within 180 days prior to registration as documented in the medical&#xD;
             record. HIV testing is not required for eligibility for this protocol.&#xD;
&#xD;
          -  The patient must provide study-specific informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Definitive clinical or radiologic evidence of metastatic disease, as documented by the&#xD;
             treating institution.&#xD;
&#xD;
          -  Prior radiotherapy to the ipsilateral chest wall or ipsilateral breast or thorax.&#xD;
             Individuals with prior radiotherapy in the contralateral breast or chest wall are&#xD;
             eligible.&#xD;
&#xD;
          -  Any radiation therapy for the currently diagnosed breast cancer prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Dermatomyositis with a CPK level above normal or with an active skin rash or&#xD;
             scleroderma.&#xD;
&#xD;
          -  Other non-malignant systemic disease that would preclude the patient from receiving&#xD;
             study treatment or would prevent required follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Bekelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oren Cahlon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shannon MacDonald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Bekelman, MD</last_name>
    <phone>215-662-7266</phone>
    <email>bekelman@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hien Lu</last_name>
    <phone>215-662-6694</phone>
    <email>hien.lu@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drexell H. Boggs, MD</last_name>
      <phone>205-934-5670</phone>
      <email>dboggs@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Urbanic, MD</last_name>
      <phone>858-246-0500</phone>
      <email>jurbanic@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonali Rudra, MD</last_name>
      <phone>202-444-3320</phone>
      <email>Sonali.Rudra@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Health</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Proton Therapy Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Insititute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcio Fagundes, MD</last_name>
      <phone>786-527-8044</phone>
      <email>Marciof@baptisthealth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Dvorak, MD</last_name>
      <phone>321-841-7413</phone>
      <email>Tomas.Dvorak@orlandohealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagar Patel, MD</last_name>
      <phone>404-778-1900</phone>
      <email>sagar.patel@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Proton Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Kesslering, MD</last_name>
      <phone>630-352-5350</phone>
      <email>Christy.Kesslering@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willis Knighton</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lane Rosen, MD</last_name>
      <phone>318-212-4639</phone>
      <email>lrosen@wkhs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mishra, MD</last_name>
      <phone>410-328-2328</phone>
      <email>mmishra@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Wright, MD</last_name>
      <phone>305-588-4511</phone>
      <email>jeanwright@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon MacDonald, MD</last_name>
      <phone>617-643-7250</phone>
      <email>SMACDONALD@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mass General/North Shore Cancer Center</name>
      <address>
        <city>Danvers</city>
        <state>Massachusetts</state>
        <zip>01923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James McIntyre, MD</last_name>
      <phone>978-882-6060</phone>
      <email>jfmcintyre@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McLaren Proton Therapy</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Devisetty, MD</last_name>
      <phone>810-342-3800</phone>
      <email>kiran.devisetty@mclaren.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Chen, MD</last_name>
      <phone>248-551-7038</phone>
      <email>pchen@beaumont.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Mutter, MD</last_name>
      <phone>507-284-2511</phone>
      <email>mutter.robert@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University, St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imran Zoberi, MD</last_name>
      <phone>314-747-7236</phone>
      <email>izoberi@radonc.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of NJ</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Haffty, MD</last_name>
      <phone>732-253-3939</phone>
      <email>hafftyb@cinj.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ProCure Proton Therapy Center</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Tsai, MD</last_name>
      <phone>732-357-2600</phone>
      <email>henry.tsai@nj.procure.com</email>
    </contact>
    <investigator>
      <last_name>Henry Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Proton Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Choi, MD</last_name>
      <phone>646-968-9031</phone>
      <email>ichoi@nyproton.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lior Braunstein, MD</last_name>
      <phone>201-775-7446</phone>
      <email>Braunstl@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Meier, MD</last_name>
      <phone>513-584-7698</phone>
      <email>meierta@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals, Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Lyons, MD</last_name>
      <phone>216-896-1755</phone>
      <email>janice.lyons@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozer Algan, MD</last_name>
      <phone>405-271-5641</phone>
      <email>Ozer-algan@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma City Procure</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health Cancer Institute</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Weksberg, MD, PhD</last_name>
      <phone>717-724-6760</phone>
      <email>dweksberg@pinnaclehealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Freedman, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Gary Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Provision Center for Proton Therapy</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Meeks, MD</last_name>
      <phone>865-437-5252</phone>
      <email>allen.meeks@provisionproton.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hoffman, MD</last_name>
      <phone>713-792-2121</phone>
      <email>KHoffman1@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Center for Proton Therapy</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Sturgeon, MD</last_name>
      <phone>469-513-5500</phone>
      <email>jared.sturgeon@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Ming Christine Fang, MD</last_name>
      <phone>206-598-4100</phone>
      <email>lmcfang@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.radcomp.org</url>
    <description>Study website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

